Second/third/fourth line therapy with tyrosine kinase inhibitors in NSCLC

被引：0
|
作者：
Van Zandwijk, N [1 ]
Baas, P [1 ]
机构：
[1] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands
来源：
TUMORI | 2002年
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S37 / S38
页数：2
相关论文
共 50 条
  • [31] Safety profiles of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia
    Tinsley, Sara M.
    JOURNAL OF CLINICAL NURSING, 2010, 19 (9-10) : 1207 - 1218
  • [32] ROLE OF SECOND GENERATION TYROSINE KINASE INHIBITORS IN OSTEOBLASTOGENESIS
    Tibullo, D.
    Barbagallo, I.
    Giallongo, I.
    La Cava, P.
    Branca, A.
    Bartolo, Di
    Spina, E.
    Spina, P.
    Del Fabro, V.
    Conticello, C.
    Romano, A.
    Palumbo, G.
    Di Raimondo, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 519 - 519
  • [33] Second-generation inhibitors of Bruton tyrosine kinase
    Wu, Jingjing
    Liu, Christina
    Tsui, Stella T.
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
  • [34] Second-generation inhibitors of Bruton tyrosine kinase
    Jingjing Wu
    Christina Liu
    Stella T. Tsui
    Delong Liu
    Journal of Hematology & Oncology, 9
  • [35] Role of tyrosine kinase inhibitors in cancer therapy
    Arora, A
    Scholar, EM
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03): : 971 - 979
  • [36] Protein tyrosine kinase inhibitors in cancer therapy
    Boutayeb, S.
    Zakkouri, F. Z.
    Aitelhaj, M.
    Mesmoudi, M.
    Boutayeb, A.
    Boutayeb, W.
    Mrabti, H.
    Errihani, H.
    PATHOLOGIE BIOLOGIE, 2012, 60 (04): : 229 - 233
  • [37] Validation of the Meet-URO score in metastatic clear cell renal cell carcinoma patients receiving second or third-line tyrosine kinase inhibitors-immune checkpoint inhibitors combination therapy
    He, Sike
    Liu, Haoyang
    Chen, Junru
    Zeng, Hao
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [38] Is There a Clinical Benefit for Less Than a Complete Cytogenetic Response (CCyR) for Patients (Pts) with Chornic Myeloid Leukemia (CML) Receiving Tyrosine Kinase Inhibitors (TKI) as Second or Third Line Therapy?.
    Cortes, Jorge E.
    Quintas-Cardama, Alfonso
    Jabbour, Elias
    Burton, Elizabeth
    O'Brien, Susan
    Verstovsek, Srdan
    Konopleva, Marina
    Wierda, William G.
    Borthakur, Gautam
    Ravandi, Farhad
    Kantarjian, Hagop
    BLOOD, 2010, 116 (21) : 531 - 531
  • [39] Validation of the Meet-URO score in metastatic clear cell renal cell carcinoma patients receiving second or third-line tyrosine kinase inhibitors-immune checkpoint inhibitors combination therapy
    Sike He
    Haoyang Liu
    Junru Chen
    Hao Zeng
    Journal of Translational Medicine, 22
  • [40] Update on third-generation EGFR tyrosine kinase inhibitors
    Gray, Jhanelle
    Haura, Eric
    TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (06) : 360 - 362
12345